Subgroup analyses in these trials explored the correlations between immunotherapy efficacy and the patient features age; sex; region; race; line of therapy; NSCLC types; smoking status; ECOG score; PD-L1 expression; and EGFR, KRAS, or ALK gene mutation status. This evidence concerns the gene CD274 and non-small cell lung carcinoma.